Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Xeltis raises an additional €20.5m to advance aXess™ toward FDA approval and US commercial launch with Horizon 3 Healthcare as the lead investor.
PRIVATEJul 28, 2026•2 days ago
Amount Raised
€20.5 Million
Round Type
Venture - Series Unknown
EindhovenManufacturingBiotechnologyHealth Care
Investors
Horizon 3 HealthcareDa VitaEqt Life SciencesVi PartnersInvest NlEuropean Innovation Council
Description
Xeltis announced it raised an additional €20.5m from new and existing shareholders to fund the ongoing US pivotal trial of aXess™, its pioneering living vascular access solution. The funding will also facilitate the FDA submission and commercial rollout in Europe. The company aims to enhance its manufacturing capabilities and continue the advancement of its clinical programs. This financing demonstrates robust investor confidence in Xeltis' strategy.
Company Information
Company
Xeltis
Location
Eindhoven, North Brabant, Netherlands
About
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. The Company seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. Xeltis' proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient's own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place.
EindhovenManufacturingBiotechnologyHealth Care